-
A 74-year retired veterinarian presents to the emergency department (ED) with shortness of breath. He was recently diagnosed with diffuse large-cell lymphoma with prominent abdominal lymphadenopathy and positive bone marrow and has been treated with two cycles of R-CHOP.
-
In a multicenter study, critically ill patients with initial hyperlactatemia had improved outcomes (including shorter ICU stays and lower adjusted mortality) compared to control patients when they were managed for the first 8 hours with a resuscitation protocol targeted at reducing the lactate level by at least 20% every 2 hours.
-
The relationship between blood pressure and cardiovascular events remains controversial, especially in patients with coronary artery disease who may need increased pressures to have adequate myocardial perfusion.
-
Gastrointestinal (GI) bleeding is a major complication of dual anti-platelet therapy (DAPT) with aspirin and clopidogrel.
-
Marine n-3 PUFAs act as pleiotropic agents on the cardiovascular system with a diverse range of effects most of which are beneficial for patients with known cardiovascular disease and possibly, they may even have beneficial effects with regard to the primary prevention of cardiovascular disease.
-
An evaluation of medical research by the IOM establishes new RDAs for vitamin D (600-800 IU) and calcium (700-1300 milligrams).
-
Glucosamine sulfate continues to grow in popularity as a treatment for osteoarthritis. Global sales reached almost $2 billion in 2008, an increase of 60 percent over the previous five years.
-
-
Findings of this ground-breaking randomized controlled trial suggest that patients with irritable bowel syndrome who receive treatment with placebo tablets, and who are fully aware that they are taking a placebo, have significantly greater relief of symptoms compared with patients who receive no treatment at all. Accessing the placebo effect may not require deception at all.
-
The results of this well-done study suggest that a specific formulation of echinacea may offer modest benefit to people with the common cold, but that such benefit is statistically, and likely clinically, insignificant. Data from the trial relating to physician-patient interaction and clinical response have yet to be published.